Related Experiment Video
Updated: Jul 30, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Quantification of insulin-like growth factor I (IGF-I) without interference by IGF binding proteins
1Department of Physiology, Loma Linda University School of Medicine, CA 92350, USA.
Insights
A new chemiluminescent dot blot assay offers rapid Insulin-like Growth Factor-I (IGF-I) determination in cell culture media. This method avoids interference from IGF binding proteins (IGFBPs), unlike traditional radioimmunoassays.
Area of Science:
- Biochemistry
- Cell Biology
- Assay Development
Background:
- Insulin-like Growth Factor-I (IGF-I) is crucial for cell growth and differentiation.
- Accurate measurement of IGF-I in cell culture is essential for research.
- Existing methods like radioimmunoassays (RIAs) can be affected by IGF binding proteins (IGFBPs).
Purpose of the Study:
- To develop a rapid and reliable assay for quantifying IGF-I in serum-free conditioned media (CM).
- To evaluate the interference of IGFBPs in the developed assay compared to RIAs.
Main Methods:
- Development of a chemiluminescent dot blot assay for IGF-I detection.
- Testing the interference of all six IGFBPs on the dot blot assay.
- Comparison of IGF-I detection with a standard RIA using the same monoclonal antibody.
- Quantification of chemiluminescence using phosphorimager and Molecular Analyst software.
Main Results:
- The chemiluminescent dot blot assay successfully detected IGF-I in CM without interference from IGFBPs.
- All six IGFBPs bound to 125I IGF-I but did not interfere with detection on dot blots.
- A comparable RIA showed interference from IGFBP-1, IGFBP-2, and IGFBP-4.
- The dot blot assay demonstrated sensitivity (0.125-8.0 ng/mL), specificity (<1% cross-reactivity with IGF-II), and reproducibility (intra-assay variance ≤6%, inter-assay variance <12%).
Conclusions:
- The developed chemiluminescent dot blot assay provides a robust, sensitive, and specific method for IGF-I quantification in serum-free CM.
- This assay overcomes the limitations of RIAs by eliminating IGFBP interference.
- The assay is not suitable for serum or serum-containing media due to reagent sensitivity to serum components.
Abstract:
A chemiluminescent dot blot assay has been developed by our laboratory for rapid determinations of IGF-I in serum-free conditioned media (CM) collected from cultured cells. In contrast to IGF-I radioimmunoassays (RIAs), the IGF binding proteins (IGFBPs) did not interfere with the dot blot assay and did not require the laborious (and sometimes ineffective) removal of IGFBPs. Although all six IGFBPs were shown to bind to 125I IGF-I, none interfered with IGF-I detection on nitrocellulose dot blots. In contrast, an RIA using the same Oncogene monoclonal antibody (clone 82-9A) showed interference by IGFBP-1, IGFBP-2, and IGFBP-4. The IGF-I dot blot assay was sensitive (0.125-8.0 ng IGF-I), specific (assay crossreactivity with IGF-II is less than 1%), and reproducible (intra-assay variance < or = 6%; inter-assay variance < 12%) when chemiluminescence was quantified by phosphorimager and Molecular Analyst software (BioRad). The apparent sensitivity of the enhanced chemiluminescence (ECL) reagent to serum, precludes the use of this assay for IGF-I determination in serum or in serum-containing media.
More Related Videos
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Production of Pharmaceuticals

